Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.

Item

http://www.wikidata.org/entity/Q35078787

Q35078787

about

HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study.Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3.HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.8p deletion is strongly linked to poor prognosis in breast cancer.A multi-resolution textural approach to diagnostic neuropathology reporting.Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.HER2 expression status in diverse cancers: review of results from 37,992 patients.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer The assessment of HER2 status in breast cancer: the past, the present, and the future.Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients.Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: Results from a large, multicountry study.CLIP2 as radiation biomarker in papillary thyroid carcinoma.Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study.Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer.Relationship Between ADAMTS8, ADAMTS18, and ADAMTS20 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) Expressions and Tumor Molecular Classification, Clinical Pathological Parameters, and Prognosis in Breast Invasive Ductal Carcinoma Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer

P2860

Q33741544-762451EE-B623-4D33-AA94-AA71D85673B2 Q34084063-414E1E2C-5EE2-4D8B-B506-AB2A113CBB72 Q35038694-A074B910-E6A3-476A-A3E7-A8F581D1BC46 Q35810073-0A84222F-7343-4CCF-880A-4EC9D9526155 Q35903727-B9B224F2-2ABC-4C2A-99F3-BD8C91EFBBED Q36087126-7D8C3C9C-DFBF-4FD0-B670-B0BD49DDA659 Q36214952-5528598E-35C6-459B-BD0D-8515F680D1C3 Q36663072-321F99F2-5C6F-4F60-94C4-4A18EC5FD1F5 Q37682124-2F584DCC-8A72-40EF-B543-49CFAB441CF2 Q37694673-49EA4D2B-022E-4D98-9434-B9F3F9052729 Q38364900-5898EF0C-CBAA-4480-9E01-98BAABAD4D7E Q38612634-5D405AAF-5360-4775-AC64-0D9C1205E148 Q38648408-E317D90A-BF5E-4ADE-B770-20335DCE5615 Q38802932-7B1A62AD-668F-4CBD-87D1-2DCDF85197F1 Q39022194-4B77C2CB-0CA4-4828-8689-77058E684EDD Q39661792-1E84B8FC-7243-440E-AFA4-DF0EB22B457D Q40226802-C531FE64-004D-4292-B739-CDAFDC51FE3D Q40338226-E78C925D-3038-4DB0-B5A1-9A8E94AAED0C Q40391145-A27A0C98-F54F-4551-B50F-72055018BD1C Q41551352-5523A806-1FA4-43B2-96E9-FA6AF36210AA Q49909339-4B5FA616-44E2-4463-AA16-5877B77690A0 Q53095268-56297710-F109-45E1-9F57-AC8D7B91EC75 Q55008104-99014E6E-9825-4175-AAF2-C6941DFD13F9 Q55261836-52C19581-1AED-4DBB-A318-EF9FC5070A25 Q57495756-72FC945D-2270-48DB-990C-83A870BBBCC1

P2860

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.

Item

http://www.wikidata.org/entity/Q35078787

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu